LAWRENCE ANDREW FILAK JR. O.D.
Prescription History 1720150352
Optometrist in Shrewsbury, PA

NPI Status: Active since November 15, 2006

Contact Information

1 N MAIN ST
SHREWSBURY, PA
ZIP 17361
Phone: (717) 235-1873
Fax: (717) 235-2087

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for LAWRENCE ANDREW FILAK JR. O.D., an active Optometrist specialist practicing in Shrewsbury, PA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 64 documented patient claims. Among these therapy options, the most frequently utilized medication is Prednisolone Acetate, which accounts for 23 claims alone.

Medication Index

No matching medications currently found on file.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 16
30-Day Fills 29.1
Days Supply 783
PA State Average Benchmarks
Peer Average Claims123.0
Peer Average 30-Day Fills210.1
Peer Average Days Supply5,946
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.0% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $315.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.74

State Avg Cost Per Claim

$18.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Optometry
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.8
Days Supply 491
PA State Average Benchmarks
Peer Average Claims130.0
Peer Average 30-Day Fills166.3
Peer Average Days Supply4,249
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.3% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,021.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.40

State Avg Cost Per Claim

$46.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 12
30-Day Fills 14.0
Days Supply 420
PA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills78.4
Peer Average Days Supply2,297
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.9% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,448.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$787.38

State Avg Cost Per Claim

$1,073.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Tobramycin-Dexamethasone

Generic Formulation: Tobramycin/DexamethasoneSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 236
PA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply626
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.1% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $842.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$64.83

State Avg Cost Per Claim

$78.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topical preparation of tobramycin and dexamethasone that is used for treating or preventing superficial bacterial infections of the eye.

Therapeutic Applications

This medication is used to treat or prevent eye infections. This medication contains two drugs. Tobramycin belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. Dexamethasone belongs to a class of drugs called corticosteroids. It works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like LAWRENCE ANDREW FILAK JR. O.D. provides transparency into local medical care patterns within Shrewsbury, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.